CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
Cash flows from operating activities:
Net (loss) income before equity in losses of unconsolidated affiliates	$ (15,232)	$ 1,304
Adjustments to reconcile net (loss) income to cash (used in) provided by operating activities:
Depreciation and amortization	6,826	6,680
Non-cash impact of operating leases	1,321	1,050
Deferred tax benefit	(3,556)	(3,294)
Stock-based compensation	9,990	9,457
Change in fair value of contingent consideration	(294)	0
Provision for credit losses on convertible note receivable	3,499	0
Equity in losses of unconsolidated affiliates	736	529
Accretion of discounts and issuance costs	20	35
Other losses (gains), net	211	768
Changes in operating assets and liabilities (net of the effect of acquisitions):
Accounts receivable	(43)	3,046
Inventories	(9,145)	(4,080)
Lease receivables	(3,494)	(2,196)
Other assets	296	(2,208)
Accounts payable	(2,913)	(334)
Other liabilities	(4,836)	(3,603)
Net cash (used in) provided by operating activities	(16,614)	7,154
Cash flows from investing activities:
Promissory note receivable issuance	0	(9,000)
Capital expenditures	(1,093)	(546)
Proceeds from disposition of property and equipment	0	41
Net cash used in investing activities	(30,602)	(13,387)
Cash flows from financing activities:
Payment of stock issuance costs	0	(314)
Proceeds from issuance of common stock	2,245	167,198
Payments for taxes related to shares withheld for employee taxes	(5,001)	(932)
Repayments of other debt	(115)	(653)
Net cash (used in) provided by financing activities	(2,871)	165,299
Foreign exchange effect on cash and cash equivalents	(1,559)	(247)
Net (decrease) increase in cash and cash equivalents	(51,646)	158,819
Cash and cash equivalents, beginning of period	223,574	86,334
Cash and cash equivalents, end of period	171,928	245,153
Supplemental disclosure of cash flow information:
Non-cash transfers of equipment between inventory and property and equipment, net	1,535	2,562
Contingent consideration for acquisitions	3,860	1,700
Indemnity holdback and net working capital adjustment for acquisitions	867	370
Lacuna Diagnostics, Inc.
Cash flows from investing activities:
Acquisition	0	(3,882)
Biotech
Cash flows from investing activities:
Acquisition	$ (29,509)	$ 0